| 期刊簡介 | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名稱 | Journal of Hepatocellular Carcinoma LetPub Score 7.2
50 ratings
Rate
Reputation 8.7 Influence 5.6 Speed 9.6 | ||||||||||||||||||||
| 期刊簡稱 | J HEPATOCELL CARCINO | ||||||||||||||||||||
| ISSN | 2253-5969 | ||||||||||||||||||||
| h-index | N.A. | ||||||||||||||||||||
| CiteScore |
| ||||||||||||||||||||
| 自引率 (2023-2024) | 7.10%自引率趨勢 | ||||||||||||||||||||
| 掲載範囲 |
| ||||||||||||||||||||
| 官方網站 | http://www.dovepress.com/journal-of-hepatocellular-carcinoma-journal | ||||||||||||||||||||
| 在線稿件提交 | |||||||||||||||||||||
| 開放訪問 | Yes | ||||||||||||||||||||
| 出版商 | DOVE MEDICAL PRESS LTD | ||||||||||||||||||||
| 主題領域 | ONCOLOGY | ||||||||||||||||||||
| 出版國/地區 | NEW ZEALAND | ||||||||||||||||||||
| 發行頻率 | |||||||||||||||||||||
| 創刊年 | 0 | ||||||||||||||||||||
| 每年文章數 | 216每年文章數趨勢 | ||||||||||||||||||||
| 黃金OA百分比 | 99.65% | ||||||||||||||||||||
OA Related Info![]() | APC: Yes( USD3300; ) APC waiver:Check Notes Other charges: No Keywords: hepatocellular carcinoma、cancer、liver cancer、hepatitis b virus Useful LinksAims & ScopeAuthor InstructionsEditorial BoardAnonymous peer review | ||||||||||||||||||||
| Web of Science 四分位 ( 2023-2024) | WOS Quartile: Q2
| ||||||||||||||||||||
| 索引 (SCI or SCIE) | Science Citation Index Expanded | ||||||||||||||||||||
| 鏈接到PubMed Central (PMC) | https://www.ncbi.nlm.nih.gov/nlmcatalog?term=2253-5969%5BISSN%5D | ||||||||||||||||||||
| 平均審稿時間 * | 來自出版商的數據: 來自作者的數據: 16 Weeks | ||||||||||||||||||||
| 競爭力 * | 來自作者的數據: | ||||||||||||||||||||
| 參考鏈接 |
| ||||||||||||||||||||
| *所有的審稿過程指標,如接受率和審稿速度,僅限於用戶提交的稿件。因此,這些指標可能無法準確反映期刊的競爭力或速度。 | |||||||||||||||||||||
|
|
| |
| 首頁 上一頁 1 下一頁 末頁 (頁 | |
| [Journal of Hepatocellular Carcinoma] 的評論 | 撰寫評論 |
| 作者: 科研卡拉米 領域: 医学 審稿時間: 4.0 month(s) 結果: 拒稿 撰寫評論 |
2024-12-21 14:33:46 評論於 It took two months from the first submission to the review process. In the meantime, they asked for the raw data tapes, which took a long time to provide. After another two months, they told me that they had only found one reviewer and rejected my submission directly. |
| 作者: WestLBS 領域: 医学 審稿時間: 1.0 month(s) 結果: 拒稿 撰寫評論 |
2024-10-05 15:54:35 評論於 The difficulties arose when a public database + sample verification combination generated a flurry of emails before and after; 24-9-16 submission 24-9-17 asked me to confirm if ethical approval had been obtained (manuscript clearly stated, I replied that approval had been obtained) 24-9-23 asked why I needed ethical approval for the public database I was using (I clearly stated it was a combination of a database + sample verification, obviously they didn't even read the article and just talked nonsense with me) 24-9-23 the same day asked for the research plan for the clinical sample repository (including inclusion criteria) and the hospital's ethical review approval 24-9-27 asked why the head of the sample repository was not included in the list of authors (replied because the sample repository is shared by the department, not specifically collected for this study) 24-9-30 asked if this study (rather than the clinical sample repository) had obtained ethical approval, I replied that the sample repository used had obtained approval, using the sample repository for research can exempt ethical review and attached relevant regulations 24-10-2 received a template rejection email, the letter did not mention any of the above I don't know what to say, the article that I urgently wanted to publish, unexpectedly encountered such an editor, sigh |
| 作者: 柳叶刀V5 領域: 医学 審稿時間: 6.0 month(s) 結果: 拒稿 撰寫評論 |
2024-07-19 22:59:30 評論於 After waiting for two months, I was told that they couldn't find reviewers and my submission was rejected. |
| 作者: cmdl 領域: 医学 審稿時間: 1.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-11-17 15:33:27 評論於 Will articles on bioinformatics and experimental validation be accepted? |
| 作者: IT测试请忽略 領域: 医学 審稿時間: 1.0 month(s) 結果: 拒稿 撰寫評論 |
2021-03-09 14:32:38 評論於 The tumor journal is pretty good, why is no one paying attention to it? |
| 首頁 上一頁 1 下一頁 末頁 (頁 | |
Contact us